Astrazeneca PLC (AZN) Receives Overweight Rating from Barclays PLC
AZN has been the subject of a number of other reports. Leerink Swann reaffirmed an outperform rating on shares of Astrazeneca PLC in a report on Monday, March 20th. UBS AG downgraded shares of Astrazeneca PLC from a buy rating to a neutral rating and lowered their price target for the stock from $35.44 to $25.55 in a research note on Wednesday, April 5th. HSBC Holdings plc downgraded shares of Astrazeneca PLC from a hold rating to a reduce rating in a research note on Friday, April 7th. Jefferies Group LLC reissued a hold rating on shares of Astrazeneca PLC in a research note on Monday, April 10th. Finally, Credit Suisse Group raised shares of Astrazeneca PLC from an underperform rating to a neutral rating in a research note on Friday, May 12th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $33.39.
Astrazeneca PLC (NYSE AZN) opened at 30.06 on Thursday. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The company has a market cap of $76.11 billion, a P/E ratio of 19.72 and a beta of 0.74. The company’s 50 day moving average price is $33.57 and its 200 day moving average price is $31.37.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. The firm had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business’s revenue for the quarter was down 9.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.83 EPS. Equities research analysts anticipate that Astrazeneca PLC will post $1.85 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Astrazeneca PLC (AZN) Receives Overweight Rating from Barclays PLC” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/08/astrazeneca-plcs-azn-overweight-rating-reaffirmed-at-barclays-plc-updated-updated-updated.html.
The company also recently disclosed a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be paid a $0.44 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 44.92%.
Institutional investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC boosted its position in Astrazeneca PLC by 157.1% in the first quarter. Quadrant Capital Group LLC now owns 4,591 shares of the company’s stock valued at $138,000 after buying an additional 2,805 shares during the last quarter. Creative Planning boosted its position in shares of Astrazeneca PLC by 9.8% in the first quarter. Creative Planning now owns 45,321 shares of the company’s stock worth $1,411,000 after buying an additional 4,040 shares during the last quarter. Raymond James Trust N.A. boosted its position in shares of Astrazeneca PLC by 36.2% in the first quarter. Raymond James Trust N.A. now owns 53,434 shares of the company’s stock worth $1,664,000 after buying an additional 14,216 shares during the last quarter. Fulton Bank N.A. raised its stake in Astrazeneca PLC by 44.5% in the first quarter. Fulton Bank N.A. now owns 37,404 shares of the company’s stock valued at $1,164,000 after buying an additional 11,520 shares during the period. Finally, CENTRAL TRUST Co raised its stake in Astrazeneca PLC by 2.1% in the first quarter. CENTRAL TRUST Co now owns 4,499 shares of the company’s stock valued at $140,000 after buying an additional 91 shares during the period. 14.33% of the stock is owned by institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.